Therapeutic Solutions International Develops “NanoStilbene” Nanoparticle Formulation of Pterostilbene

 Patented Augmenter of Cancer Immunotherapy Successfully Manufactured

 

OCEANSIDE, Calif., March 05, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE–Therapeutics Solutions International, Inc., (OTC PINK:TSOI) announced today successful production of a stable nanoemulsion of pterostilbene from ingredients Generally Regarded as Safe (GRAS). The nanoemulsion, which is a form of pterostilbene containing nanoparticles, is covered for use in cancer immunotherapy under the Company’s issued U.S. Patent No.: 9,682,047. Pterostilbene is the active ingredient in the Company’s patented ProJuvenol product.

Pterostilbene, a more potent analogue of resveratrol, is extracted from many plants, and has been reported by others to possess ability to prevent cancer as well as to slow its growth. A freely available summary of scientific literature on pterostilbene is available at the following link http://www.projuvenol.com/lit/.

Unfortunately, the poor solubility and stability of pterostilbene has strictly restrained its applications. As a good protection and oral delivery system, an optimal nanoemulsion for pterostilbene was developed by using a low – energy emulsification method.

“Having verified nanoparticle lengths of the pterostilbene in the 100nm (nanometer) range we are excited to now scale-up our manufacturing process for commercialization. To put this in perspective the thickness of a single human hair measures approximately 75,000 nm across, meaning 750 of our nanoparticles lined up side by side would fit in the diameter of a human hair,” said Thomas Ichim, PhD, Director of Therapeutic Solutions International. “In our opinion, the small size, combined with the stability of the formulation, positions our NanoStilbene product as second-to-none in terms of effectively delivering the pterostilbene compound for a variety of uses.”

“The product derived from the ‘047 patent is currently being called “NanoStilbene”. This nanoemulsion droplet of nanoparticle pterostilbene is free from air, light, and hard environment; therefore, as a delivery system, nanoemulsion can not only improve the bioavailability of pterostilbene but also protect it from oxidation and hydrolysis, while it possesses an ability of sustained release at the same time. We hope to announce soon the availability of this product in a future release,” added Tim G Dixon, CEO of Therapeutic Solutions International.

About Therapeutic Solutions International, Inc. The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.

These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION Therapeutic Solutions International, Inc.
ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

            © 2018 GlobeNewswire, Inc.